MedPath

SECOND GENOME

🇺🇸United States
Ownership
-
Established
2010-01-01
Employees
-
Market Cap
-
Website
http://www.secondgenome.com/

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

Phase 2
Terminated
Conditions
Nonalcoholic Steatohepatitis
Interventions
Drug: Placebo
First Posted Date
2018-09-18
Last Posted Date
2019-07-11
Lead Sponsor
Second Genome
Target Recruit Count
9
Registration Number
NCT03676231
Locations
🇺🇸

Second Genome Clinical Site 406, Tucson, Arizona, United States

🇺🇸

Second Genome Clinical Site 403, Panorama City, California, United States

🇺🇸

Second Genome Clinical Site 407, Clarksville, Tennessee, United States

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath